ATP7B and ovarian carcinoma: Moreover, lung cancer patients who have higher ATP7A expression exhibit poorer responses to cisplatin-based chemotherapy [25], and ATP7B and ATP7A are associated with resistance to cisplatin-based drugs in breast and ovarian cancer [26].